Blood-based Biomarkers for Diagnosis of Alzheimer's

Launched by HELSE STAVANGER HF · Dec 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test that aims to diagnose Alzheimer’s disease (AD) more easily and affordably than current methods, which often involve expensive procedures like spinal taps or brain scans. The goal is to see if this blood test can accurately identify people with Alzheimer’s in a regular doctor's office setting. Researchers believe that this test will be reliable in diagnosing Alzheimer’s disease among patients who are suspected of having dementia based on their doctor's evaluation.

To participate in this trial, people need to be referred by their general practitioner (GP) if they show signs of possible dementia. It's important to note that individuals who are unable to give consent, have severe mental health issues, or do not wish to be referred to a memory clinic will not be eligible. Participants can expect to provide a blood sample and may receive further assessments to help with the diagnosis. This study could lead to a more accessible way to diagnose Alzheimer’s, which may help many people get the support they need sooner.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening
• Exclusion Criteria:
• • Lack of capacity for consent as judged by the GP.
• • Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
• • Patients not wanting to be referred to the memory outpatient clinic.